Viking Therapeutics shares hit a 10-month high after Canaccord Genuity raised its price target and said the company obesity pipeline is worth far more than its current valuation. The Metsera outcome renewed interest in independent obesity-drug developers, while retail traders highlighted potential Phase 3 updates and near-term catalysts.